By: Maribel Yoo On: June 10, 2019 In: Nexus Strategy, Portfolio Comments: 0
Thrive Logo

Thrive Sciences is developing a liquid biopsy-based diagnostic test to detect cancer in its earlier, pre-metastatic stages. The Company’s vision is that a high-quality, affordable, “multi-cancer” test for healthy adults, administered by primary care physicians as part of routine medical care, will enable proactive cancer management that significantly prolongs and improves patient quality of life, potentially saving hundreds of thousands of lives annually.  Thrive has exclusively licensed the CancerSEEK technology, developed by Dr. Bert Vogelstein and his colleagues at Johns Hopkins, to serve as the basis of their commercial offering.

Deal Source

Dr. Bert Vogelstein

Board Representation

R. Jacob Vogelstein